<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02873468</url>
  </required_header>
  <id_info>
    <org_study_id>EMS0718 - FLORENCE</org_study_id>
    <nct_id>NCT02873468</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Three Doses of Florence Oral Suspension in Adults With Eosinophilic Esophagitis</brief_title>
  <official_title>Randomized, Double-blind, Multicentric, Parallel, National, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Three Doses of Florence Oral Suspension in Adults With Eosinophilic Esophagitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of three doses of Florence oral&#xD;
      suspension on changes of eosinophilic infiltration in esophageal biopsies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants presenting a histological response, defined as the presence of ≤ 6 eosinophils/high-power field, at the end of treatment.</measure>
    <time_frame>100 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events recorded during the study.</measure>
    <time_frame>170 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Eosinophilic Esophagitis</condition>
  <arm_group>
    <arm_group_label>Florence 30</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Florence 60</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Florence 90</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Florence 30 μg/mL</intervention_name>
    <description>10 mL, oral, twice a day.</description>
    <arm_group_label>Florence 30</arm_group_label>
    <other_name>EMS oral suspension</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Florence 60 μg/mL</intervention_name>
    <description>10 mL, oral, twice a day.</description>
    <arm_group_label>Florence 60</arm_group_label>
    <other_name>EMS oral suspension</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Florence 90 μg/mL</intervention_name>
    <description>10 mL, oral, twice a day.</description>
    <arm_group_label>Florence 90</arm_group_label>
    <other_name>EMS oral suspension</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>10 mL, oral, twice a day.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Florence placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed consent;&#xD;
&#xD;
          -  Participants aged 18 years or more;&#xD;
&#xD;
          -  Participants diagnosed with eosinophilic esophagitis, defined as:&#xD;
&#xD;
               1. Presence of symptoms of esophageal dysfunction intermittently or continuously&#xD;
                  during previous week to the screening visit;&#xD;
&#xD;
               2. Eosinophilic esophageal inflammation with ≥ 15 eosinophils/high-power field, in&#xD;
                  the screening endoscopy;&#xD;
&#xD;
               3. Exclusion of other causes of esophageal eosinophilia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any clinical and laboratory findings that, in the judgment of the investigator, may&#xD;
             interfere with the safety of research participants;&#xD;
&#xD;
          -  Participants with a stricture on endoscopy that prevents passage of the endoscope;&#xD;
&#xD;
          -  History of alcohol abuse or drug use;&#xD;
&#xD;
          -  Use of concomitant therapies for any reason that may affect the assessment;&#xD;
&#xD;
          -  History of gastroesophageal surgery;&#xD;
&#xD;
          -  History of the abnormal gastrointestinal disorder;&#xD;
&#xD;
          -  Another disorder that causes esophageal eosinophilia;&#xD;
&#xD;
          -  Pregnancy or risk of pregnancy and lactating patients;&#xD;
&#xD;
          -  Participants with known allergy, contraindication or hypersensitivity to the&#xD;
             components of the medicine used in the clinical trial;&#xD;
&#xD;
          -  Participation in clinical trial in the year prior to this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Monalisa FB Oliveira, MD</last_name>
    <phone>+551938879851</phone>
    <email>pesquisa.clinica@ems.com.br</email>
  </overall_contact>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 16, 2016</study_first_submitted>
  <study_first_submitted_qc>August 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2016</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Eosinophilic Esophagitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

